Effect of IL-1beta, PGE(2), and TGF-beta1 on the expression of OPG and RANKL in normal and osteoporotic primary human osteoblasts.
The RANKL/RANK/OPG pathway is essential for bone remodeling regulation. Many hormones and cytokines are involved in regulating gene expression in most of the pathway components. Moreover, any deregulation of this pathway can alter bone metabolism, resulting in loss or gain of bone mass. Whether osteoblasts from osteoporotic and nonosteoporotic patients respond differently to cytokines is unknown. The aim of this study was to compare the effect of interleukin (IL)-1beta, proftaglandin E(2) (PGE(2)), and transforming growth factor-beta1 (TGF-beta1) treatments on OPG and RANKL gene expression in normal (n = 11) and osteoporotic (n = 8) primary osteoblasts. OPG and RANKL mRNA levels of primary human osteoblastic (hOB) cell cultures were assessed by real-time PCR. In all cultures, OPG mRNA increased significantly in response to IL-1beta treatment and decreased in response to TGF-beta1 whereas PGE(2) treatment had no effect. RANKL mRNA levels were significantly increased by all treatments. Differences in OPG and RANKL responses were observed between osteoporotic and nonosteoporotic hOB: in osteoporotic hOB, the OPG response to IL-1beta treatment was up to three times lower (P = 0.009), whereas that of RANKL response to TGF-beta1 was five times higher (P = 0.002) after 8 h of treatment, as compared with those in nonosteoporotic hOBs. In conclusion, osteoporotic hOB cells showed an anomalous response under cytokine stimulation, consistent with an enhanced osteoclastogenesis resulting in high levels of bone resorption.
Internal Medicine, URFOA, IMIM, RETICEF, Hospital del Mar, Autonomous University of Barcelona, Barcelona, Spain. sjurado@imim.es
Susana
S
Jurado
Natalia
N
Garcia-Giralt
Adolfo
A
Díez-Pérez
Pedro
P
Esbrit
Guy
G
Yoskovitz
Lídia
L
Agueda
Roser
R
Urreizti
Lluís
L
Pérez-Edo
Guillem
G
Saló
Leonardo
L
Mellibovsky
Susana
S
Balcells
Daniel
D
Grinberg
Xavier
X
Nogués
D016022:Case-Control Studies; D002478:Cells, Cultured; D015232:Dinoprostone / Q000494:pharmacology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D053583:Interleukin-1beta / Q000494:pharmacology*; D010006:Osteoblasts / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D010024:Osteoporosis / Q000235:genetics*; D053244:Osteoprotegerin / Q000235:genetics*; D016133:Polymerase Chain Reaction; D053245:RANK Ligand / Q000235:genetics*; D053773:Transforming Growth Factor beta1 / Q000494:pharmacology*
D053583:Interleukin-1beta; D053244:Osteoprotegerin; D053245:RANK Ligand; C505688:TNFSF11 protein, human; D053773:Transforming Growth Factor beta1; D015232:Dinoprostone